Abstract: Disclosed herein are novel methodologies of treating fragile X syndrome and related disorders by inhibiting mGlu5-relevant signaling pathways via the reduction of ?-arrestin2 protein levels or the diminution of mGlu5 and ?-arrestin2 protein interactions.

Abstract: The invention generally relates to methods for diagnosing autism spectrum disorders. In certain embodiments, the invention provides a method for diagnosing presence or increased risk of developing an autism spectrum disorder in a subject.

Abstract: Amblyopia is a prevalent form of visual impairment that generally arises during infancy and early childhood when inputs to the visual cortex form the two eyes are poorly balanced. Disclosed herein are methods involving retinal inactivation of at least one retina to treat visual impairment in the form of amblyopia or other conditions.

Abstract: The invention generally relates to compositions and methods for diagnosing autism spectrum disorders. In certain embodiments, the invention provides a method for diagnosing presence or increased risk of developing an autism spectrum disorder in a subject.

Abstract: The invention generally relates to methods for diagnosing autism spectrum disorders. In certain embodiments, the invention provides a method for diagnosing presence or increased risk of developing an autism spectrum disorder in a subject.

Abstract: Disclosed herein are novel methodologies of treating fragile X syndrome and related disorders by inhibiting mG1u5-relevant signaling pathways via the reduction of ?-arrestin2 protein levels or the diminution of mG1u5 and ?-arrestin2 protein interactions.

Abstract: Amblyopia is a prevalent form of visual impairment that generally arises during infancy and early childhood when inputs to the visual cortex form the two eyes are poorly balanced. Disclosed herein are methods involving retinal inactivation of at least one retina to treat visual impairment in the form of amblyopia or other conditions.

Abstract: The present disclosure provides methods of using GSK3?-selective inhibitors for treating Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder. The GSK3?-selective inhibitors include compounds of Formula I-A. The present disclosure also provides methods of using GSK3?-selective inhibitors for treating a mood disorder, post-traumatic stress disorder (PTSD), psychiatric disorder, diabetes, and neurodegenerative disorder. The GSK3?-selective inhibitors include compounds of Formula I-B.

Abstract: The invention generally relates to compositions and methods for diagnosing autism spectrum disorders. In certain embodiments, the invention provides a method for diagnosing presence or increased risk of developing an autism spectrum disorder in a subject.

Abstract: The invention generally relates to compositions and methods for diagnosing autism spectrum disorders. In certain embodiments, the invention provides a method for diagnosing presence or increased risk of developing an autism spectrum disorder in a subject.